By Erik L. Ridley, staff writer
    November 15, 2010

    Tuesday, November 30 | 10:30 a.m.-10:40 a.m. | SSG13-01 | Room S403A
    A University of Chicago team will provide an update on its development of computer-aided detection (CAD) software for addressing hepatocellular carcinoma (HCC), according to this paper to be presented on Tuesday morning.

    While contrast-enhanced hepatic CT has been deployed to detect and characterize HCC, this can be a difficult mission. The density of HCC is often similar to that of normal liver parenchyma and benign tumors, said presenter Jianwu Xu, PhD.

    To help with this dilemma, the research group has been developing a CAD scheme for HCC that makes use of both the arterial and portal-venous phases of contrast-enhanced CT.

    Confirming their hypothesis, the researchers found that CAD with both of these phases of contrast-enhanced CT images achieved better performance than with only the arterial-phase image, Xu said.

    "Moreover, our [CAD] scheme with both arterial and portal-venous phases of CT images achieved a very low false-positive rate with high sensitivity, which paved the way for clinical usage of [CAD] in aiding radiologists in detection of HCCs," Xu told "The study also suggested that we might further improve the [CAD] performance by combining other phases, such as precontrast and equilibrium phases, of hepatic CT images."

    Last Updated np 11/12/2010 10:41:59 AM

    || About || Advertising || || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2023 All Rights Reserved.